ATE450514T1 - Piperazinylalkylpyrazol-derivate zur verwendung als selektive calciumkanalblocker des t-typs und verfahren zu ihrer herstellung - Google Patents

Piperazinylalkylpyrazol-derivate zur verwendung als selektive calciumkanalblocker des t-typs und verfahren zu ihrer herstellung

Info

Publication number
ATE450514T1
ATE450514T1 AT06254404T AT06254404T ATE450514T1 AT E450514 T1 ATE450514 T1 AT E450514T1 AT 06254404 T AT06254404 T AT 06254404T AT 06254404 T AT06254404 T AT 06254404T AT E450514 T1 ATE450514 T1 AT E450514T1
Authority
AT
Austria
Prior art keywords
piperazinylalkylpyrazole
derivatives
calcium channel
production
channel blockers
Prior art date
Application number
AT06254404T
Other languages
English (en)
Inventor
Ghil-Soo Nam
Kyung-Il Choi
Hun-Yeong Koh
Ae-Nim Pae
Hye-Whon Rhim
In-Sung Choi
Original Assignee
Korea Inst Sci & Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Inst Sci & Tech filed Critical Korea Inst Sci & Tech
Application granted granted Critical
Publication of ATE450514T1 publication Critical patent/ATE450514T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT06254404T 2005-08-26 2006-08-22 Piperazinylalkylpyrazol-derivate zur verwendung als selektive calciumkanalblocker des t-typs und verfahren zu ihrer herstellung ATE450514T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020050079095A KR100654328B1 (ko) 2005-08-26 2005-08-26 피페라지닐알킬피라졸계 t-타입 칼슘 채널 억제 화합물 및이의 제조방법

Publications (1)

Publication Number Publication Date
ATE450514T1 true ATE450514T1 (de) 2009-12-15

Family

ID=37529291

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06254404T ATE450514T1 (de) 2005-08-26 2006-08-22 Piperazinylalkylpyrazol-derivate zur verwendung als selektive calciumkanalblocker des t-typs und verfahren zu ihrer herstellung

Country Status (5)

Country Link
US (1) US7544686B2 (de)
EP (1) EP1757590B1 (de)
KR (1) KR100654328B1 (de)
AT (1) ATE450514T1 (de)
DE (1) DE602006010776D1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100882925B1 (ko) 2007-06-14 2009-02-10 한국과학기술연구원 세로토닌 5-ht₃a 길항적 효과를 갖는 피라졸 유도체함유 약제 조성물
KR101014887B1 (ko) 2008-06-26 2011-02-15 한국과학기술연구원 칼슘이온 채널 조절제로서 유효한 이미다졸릴알킬카르보닐유도체 및 그의 제조방법
KR101052065B1 (ko) 2008-10-15 2011-07-27 한국과학기술연구원 칼슘이온 채널 조절제로서 유효한 피라졸릴메틸아민-피페라진 유도체와 이의 제조방법
ES2565193T3 (es) 2010-07-15 2016-04-01 Sumitomo Dainippon Pharma Co., Ltd. Compuesto de pirazol
CN103298468A (zh) 2011-02-01 2013-09-11 协和发酵麒麟株式会社 稠环杂环衍生物
US9540366B2 (en) 2012-07-31 2017-01-10 Kyowa Hakko Kirin Co., Ltd. Ring-fused heterocyclic compound
JP2016536295A (ja) 2013-10-17 2016-11-24 ダウ アグロサイエンシィズ エルエルシー 有害生物防除性化合物の製造方法
KR20160074540A (ko) 2013-10-17 2016-06-28 다우 아그로사이언시즈 엘엘씨 살충성 화합물의 제조 방법
MX2016004942A (es) 2013-10-17 2016-06-28 Dow Agrosciences Llc Procesos para la preparacion de compuestos plaguicidas.
CA2925952A1 (en) 2013-10-17 2015-04-23 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
CN105636442B (zh) 2013-10-17 2018-04-27 美国陶氏益农公司 制备杀虫化合物的方法
CN105636445B (zh) 2013-10-17 2018-12-07 美国陶氏益农公司 制备杀虫化合物的方法
CA2925873A1 (en) 2013-10-17 2015-04-23 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
DK3152199T3 (en) * 2014-06-03 2018-11-26 Idorsia Pharmaceuticals Ltd PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS
EP3186229A4 (de) 2014-07-31 2018-01-10 Dow AgroSciences LLC Verfahren zur herstellung von 3(-3-chlor-1h-pyrazol-1-yl)pyridin
AR098108A1 (es) 2014-07-31 2016-05-04 Dow Agrosciences Llc Proceso para la preparación de 3-(3-cloro-1h-pirazol-1-il)piridina
JP2017523163A (ja) 2014-07-31 2017-08-17 ダウ アグロサイエンシィズ エルエルシー 3−(3−クロロ−1h−ピラゾール−1−イル)ピリジンの製造方法
CN107074774A (zh) 2014-08-19 2017-08-18 美国陶氏益农公司 制备3‑(3‑氯‑1h‑吡唑‑1‑基)吡啶的方法
WO2016039781A1 (en) 2014-09-12 2016-03-17 Dow Agrosciences Llc Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
WO2017070680A1 (en) 2015-10-22 2017-04-27 Cavion Llc Methods for treating angelman syndrome and related disorders
CN110139853B (zh) 2016-12-29 2023-06-16 美国陶氏益农公司 用于制备杀有害生物化合物的方法
CN110325036B (zh) 2016-12-29 2021-10-26 美国陶氏益农公司 用于制备杀虫化合物的方法
CN110545806A (zh) 2017-02-15 2019-12-06 卡维昂公司 钙通道抑制剂
US11324733B2 (en) 2017-04-26 2022-05-10 Cavion, Inc. Methods for improving memory and cognition and for treating memory and cognitive disorders
TWI879741B (zh) 2018-10-03 2025-04-11 美商卡凡恩公司 以(r)-2-(4-異丙基苯基)-n-(1-(5-(2,2,2-三氟乙氧基)吡啶-2-基)乙基)乙醯胺治療自發性震顫
KR20220066252A (ko) 2019-07-11 2022-05-24 프락시스 프리시젼 메디신즈, 인크. T형 칼슘 채널 조절제의 제형 및 이의 사용 방법
WO2025255502A1 (en) 2024-06-07 2025-12-11 Cavion, Inc. PYRIDYL AMIDE Cav3 CHANNEL MODULATORS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032526A (en) 1975-10-02 1977-06-28 American Cyanamid Company 1,2-dimethyl-3 or 5-piperazinyl-pyrazolium salts
EP0241053B1 (de) 1986-02-27 1992-11-11 Duphar International Research B.V Aryl-substituierte(N-piperidinyl)methyl und (N-piperazinyl)methylazole mit antipsychotischer Wirkung
FR2672052B1 (fr) 1991-01-28 1995-05-24 Esteve Labor Dr Derives d'aryl (ou heteroaryl)-piperazinyl-alkyl-azoles, leur preparation et leur application en tant que medicaments.
JPH09227524A (ja) * 1996-02-29 1997-09-02 Taisho Pharmaceut Co Ltd フェニルピラゾール誘導体
US5808088A (en) 1997-04-30 1998-09-15 Roche Colorado Corporation Preparation of mibefradil via an acetamide anion

Also Published As

Publication number Publication date
EP1757590A1 (de) 2007-02-28
EP1757590B1 (de) 2009-12-02
US20070049604A1 (en) 2007-03-01
DE602006010776D1 (de) 2010-01-14
US7544686B2 (en) 2009-06-09
KR100654328B1 (ko) 2006-12-08

Similar Documents

Publication Publication Date Title
ATE450514T1 (de) Piperazinylalkylpyrazol-derivate zur verwendung als selektive calciumkanalblocker des t-typs und verfahren zu ihrer herstellung
TW200517109A (en) Substituted pyridinones
AP1822A (en) Substituted pyridinones as modulators of P38 MAP kinase.
WO2009063202A3 (en) Use of crth2 antagonist compounds
MY148429A (en) Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
NO20081315L (no) Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
WO2005013892A3 (en) Hydrolytically-resistant boron-containing therapeutics and methods of use
ATE464308T1 (de) Stereoisomere verbindungen und verfahren zur behandlung von erkrankungen des magen-darm-trakts und des zentralen nervensystems
PL1694318T3 (pl) (S)-2-N-propyloamino-5-hydroksytetrahydronaftalen jako D3-agonistyczny środek terapeutyczny
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
TNSN07165A1 (en) Organic compounds
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
MA32943B1 (fr) Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique
DE60311869D1 (de) Kristalline cefdinirsalze
DE602004021358D1 (de) Benzosulfonamide derivate, deren verfahren zum herstellung, und deren verwendung zur behandlung von schmerzen
TW200637860A (en) Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same
EP1627635A3 (de) Benzothiazolium Verbindungen zur Verwendung in Methoden zur Hemmung der NO Produktion und von TNF alpha und zur Behandlung von Coronavirus Infektionen
NO20052699L (no) 4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gastrointestinale lidelser.
DE602004019778D1 (de) Verwendung von 2-amino-1,3-propandiolderivaten zur herstellung eines medikaments zur behandlung von bestimmten schmerzen
MX2009005242A (es) Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo.
UA86873C2 (en) SUBSTITUTED ARYL 1,4-PYRAZlNE DERIVATIVES
DE60310975D1 (de) Verwendung von epothilone zur behandlung hyperparathyreoidismus
ATE485820T1 (de) Verwendung von n-(dibenz (b,f)oxepin-10-ylmethyl)-n-methyl-n-prop-2-inyl min (omigapil) zur prophylaxe und/oder behandlung von muskeldystrophie
UA81405C2 (en) Substituted pyridinones as modulators of p38 map kinase

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties